Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CES1 | P23141 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CES2 | O00748 | 3/20 | 1.00 |
| ▸ | KDM1A | O60341 | 3/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 3/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | IDO1 | P14902 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrotanshinone I SCHEMBL29351163 | 1.00 | TDP1 (1.00) | TDP1MAPTCES1MEN1KMT2A | |
| Dihydrotanshinone I SCHEMBL29355397 | 1.00 | TDP1 (1.00) | TDP1MAPTCES1MEN1KMT2A | |
| Dihydrotanshinone I SCHEMBL5940466 | 1.00 | TDP1 (1.00) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL13568194 | 0.90 | TDP1 (0.81) | TDP1MAPTCES1MEN1KMT2A | |
| Dihydroisotanshinone Ii SCHEMBL16421136 | 0.90 | TDP1 (0.81) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL24191942 | 0.90 | TDP1 (0.81) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL25704340 | 0.76 | MEN1 (0.62) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL8199773 | 0.74 | MEN1 (0.63) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL16421122 | 0.74 | MEN1 (0.63) | TDP1MAPTCES1MEN1KMT2A | |
| SCHEMBL17465219 | 0.72 | MAPT (0.56) | TDP1MAPTCES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361288-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC NEPHROPATHY COMPRISING THE ACTIVITY INHIBITOR OF TENC1 | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2016-12-15 | — | — | US | claimed |
| CN-119157886-A | Application of dihydrotanshinone I in preparation of medicines for treating cerebral cavernous vascular malformation | 南京中医药大学 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024162590-A1 | COMPOSITION FOR PREVENTING OR TREATING PROSTATIC HYPERTROPHY, CONTAINING, AS ACTIVE INGREDIENTS, SALVIA MILTIORRHIZA BUNGE EXTRACT, METAL MINERAL DIAMINATE AND URIDINE | 주식회사 건강중심주의 | 2024-08-08 | — | — | WO | disclosed |
| WO-2023051088-A1 | USE OF DIHYDROTANSHINONE I IN PREPARATION OF NRF2 INHIBITOR | 浙江中医药大学 | 2023-04-06 | — | — | WO | disclosed |
| US-20220008376-A1 | INHIBITORS OF TYPE 3 SECRETION SYSTEM AND ANTIBIOTIC THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| EP-3019162-B1 | DAN SHEN EXTRACTS AND COMPOUNDS | DE WITTE PETER (BE) | 2021-05-19 | — | — | EP | disclosed |
| WO-2021086120-A1 | COMPOSITION, COMPRISING SALVIA MILTIORRHIZA BUNGE EXTRACT AS ACTIVE INGREDIENT, FOR PREVENTION OR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA OR ALOPECIA | 주식회사 큐롬바이오사이언스 | 2021-05-06 | — | — | WO | disclosed |
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2020-06-23 | — | — | US | disclosed |
| US-20190241516-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI TRENTO (IT) | 2019-08-08 | — | — | US | disclosed |
| WO-2017216732-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2017-12-21 | — | — | WO | disclosed |
| EP-2532388-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| EP-2532389-A2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | Md Bioalpha Co., Ltd. (KR) | 2012-12-12 | — | — | EP | disclosed |
| US-20100292318-A1 | ANTIBACTERIAL COMPOSITION COMPRISING SALVIA EXTRACTS | BOTANIC CENTURY (BEIJING) CO. LTD. (CN) | 2010-11-18 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MD BIOALPHA CO., LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| WO-2008133441-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2008-11-06 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | SLC25A20, SLC25A1, PC | TDP1 500/4885MAPT 292/4885CES1 352/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | TDP1 318/4885MAPT 308/4885CES1 614/4885 |
| US-20190241516-A1 | AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | AZI2, TPMT, TYMS | TDP1 1910/4885MAPT 4359/4885CES1 2178/4885 |
| US-20220008376-A1 | INHIBITORS OF TYPE 3 SECRETION SYSTEM AND ANTIBIOTIC THERAPY | PRSS3, GTF3C3, SEC23A | TDP1 3843/4885MAPT 4232/4885CES1 986/4885 |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | TDP1 1435/4885MAPT 1685/4885CES1 131/4885 |
| US-20100292318-A1 | ANTIBACTERIAL COMPOSITION COMPRISING SALVIA EXTRACTS | SRI, PSD, SRRT | TDP1 3857/4885MAPT 3706/4885CES1 3814/4885 |
| US-10689342-B2 | Aza-tanshinone derivatives, process for their preparation and their use in therapy | AZI2, TPMT, TYMS | TDP1 1910/4885MAPT 4359/4885CES1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.